Bio2 Technologies to begin enrolling patients in cervical interbody fusion device trial: 3 insights

Written by Mackenzie Garrity | November 13, 2018 | Print  |

Bio2 Technologies received FDA approval to begin enrolling patients in an investigational device exemption clinical study to evaluate Vitrium as a cervical interbody fusion device.

Here are three insights:

1. The company will evaluate Vitrium as a structural device that facilitates bone remodeling through a gradual conversion from the device to the patient's own bone.

2. Vitrium is composed of bioactive glass.

3. The randomized, controlled, non-inferiority pivotal study will evaluate Vitrium's safety and effectiveness with a twelve-month endpoint. Vitrium is currently in commercial use under 510(k) clearance as a bone graft substitute.

"Spine implant manufacturers are incorporating incremental improvements to PEEK and titanium interbody devices in an attempt to achieve better bony integration," said Bio2 Technologies CEO Paul Nichols. "Vitrium offers the ideal clinical paradigm, achieving fusion exclusively with the patient's own newly regenerated bone, with no foreign material remaining the fusion mass."

More articles on biologics:
3 things to know about Kuros Biosciences' CEO
3 things to know about Histogenics
Imagion Biosystems incorporates 'printer & ink' business model for medical imaging

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months